Browsing Tag
oncology pipeline
6 posts
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.
Is BioNTech finally breaking out of its COVID shadow? The case for its oncology comeback
Discover how BioNTech is transforming from COVID-19 pioneer to oncology powerhouse, led by ADC success and mRNA innovations. Read more now.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.
CureVac stock surges as BioNTech announces strategic mRNA-focused acquisition
BioNTech acquires CureVac in a $1.25B all-stock deal to expand its mRNA cancer pipeline. Includes stock insights, premium terms, and investor sentiment.
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused…